阿托伐他汀钙联合阿司匹林对冠心病患者血脂及炎性因子水平的影响

Effects of the combination of atorvastatin and aspirin on blood lipids and inflammation cytokines in patients with coronary heart disease

目的:探讨阿托伐他汀联合阿司匹林对冠心病患者血脂及炎性因子水平的影响。方法:将我院2015年1月到2016年12月期间收治的120例冠心病患者作为研究对象,随机分为对照组和研究组,每组60例。在常规治疗的基础上,对照组患者口服阿司匹林,2次·d^(-1),50 mg·次^(-1),研究组患者在对照组基础上加服阿托伐他,2次·d^(-1),10mg·次^(-1),两组患者均连续4w。比较两组患者治疗前、后总胆固醇(Total cholestrol,TC)、三酰甘油(Triglyceride,TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(High-density lipoprotein cholesterol,HDL-C)、一氧化氮(Nitric oxide,NO)、肿瘤坏死因子(Tumour necrosis factor-α,TNF-α)、C-反应蛋白(C-reaction protein,CRP)、白细胞介素-4(Interleukin-4,IL-4)水平及关节痛、皮疹等不良反应发生情况。结果:治疗后,研究组患者的TC、TG、LDL-C、TNF-α、CRP水平均明显小于对照组,HDL-C、NO、IL-4水平明显高于对照组,差异具有统计学意义(P<0.05);两组不良反应发生情况比较,差异无统计学意义(P>0.05。结论:阿托伐他汀与阿司匹林联合治疗冠心病可降低血脂和炎性因子水平,安全性较高。

Objective：To investigate the effects of the combination of atorvastatin and aspirin on blood lipids and inflammation cytokines in patients with coronary heart disease.Methods：One hundred and twenty patients with coronary heart disease admitted in our hospital from January 2015 to December 2016 were randomly divided into the control group and the test group with 60 cases in each group.According to conventional treatment,patients in the control group were treated with aspirin 50 mg Bid for 4 weeks.Patients in the test group were treated with 10 mg atorvastatin calcium Bid plus aspirin 50 mg Bid for 4 weeks.Serum total cholesterol（TC）,three glycerol（TG）,low density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,nitric oxide（NO）,tumor necrosis factor-α（TNF-α）,C-reaction protein（CRP）,interleukin-4 levels and joint pain,rash and other adverse reactions were measured and compared before and after treatment.Results：After treatment,the levels of TC,TG,LDL-C,TNF-α,and CRP in the test group were significantly lower than those in the control group.And the levels of HDL-C,NO and IL-4 in the test group were significantly higher than those in the control group（P〈0.05）.There was no significant difference in adverse reactions between the two groups（P〈0.05）.Conclusion：Atorvastatin combined with aspirin can reduce blood lipids and inflammation cytokines in patients with coronary heart disease,and it has higher safety.